Form 4: Gyre Therapeutics COO Trades Shares
Statement of Changes in Beneficial Ownership
Gyre Therapeutics Chief Operating Officer Ye Weiguo reported transactions involving the acquisition and sale of company common stock and stock options.
Summary
- Ye Weiguo, Chief Operating Officer of Gyre Therapeutics, Inc., engaged in several transactions on May 22, 2026, and May 26, 2026.
- On May 22, 2026, 3,500 shares of common stock were acquired at a price of $0.75 per share, increasing the total beneficial ownership to 703,500 shares.
- On the same day, 3,500 shares of common stock were sold at a weighted average price of $6.08 per share, resulting in 700,000 shares beneficially owned.
- On May 26, 2026, an additional 4,000 shares of common stock were acquired at $0.75 per share, bringing the total beneficial ownership to 704,000 shares.
- Also on May 26, 2026, 4,000 shares of common stock were sold at a weighted average price of $6.1001 per share, leaving 700,000 shares beneficially owned.
- The filing also notes the exercise of stock options: 3,500 options were exercised on May 22, 2026, and 4,000 options were exercised on May 26, 2026. These options have an exercise price of $0.75 and an expiration date of October 31, 2030.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it reports routine insider transactions without indicating significant positive or negative developments for the company.
Positives
- Acquisition of 7,500 shares of common stock at a favorable price of $0.75 per share on May 22 and May 26, 2026.
- Vested stock options were exercised, indicating potential for further equity participation.
Negatives
- Sale of 7,500 shares of common stock at prices significantly higher than the acquisition price, indicating a realization of gains by the reporting person.
- The weighted average sale price for shares sold on May 22 was $6.08, and on May 26 was $6.1001, suggesting a divestment at a substantial profit compared to the option exercise price.
Future Outlook
The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The reported activity by the COO of Gyre Therapeutics indicates a realization of gains on vested stock options and a strategic adjustment of holdings, which is common for executives.
Stakeholder Impact
- Shareholders may observe insider activity, which can sometimes influence market perception, though these transactions appear to be routine option exercises and sales.
Key Dates
| Date | Description |
|---|---|
| 05/22/2026 | Earliest transaction date reported; acquisition and sale of common stock and exercise of stock options. |
| 05/26/2026 | Date of additional acquisition and sale of common stock and exercise of stock options. |
| 05/27/2026 | Date of signature on the filing. |
| 10/31/2030 | Expiration date for the exercised stock options. |
Keywords
Form 4, SEC Filing, Insider Trading, Stock Options, Common Stock, Gyre Therapeutics, Ye Weiguo, Beneficial Ownership, Securities Exchange Act
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.